Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
JCR Pharmaceuticals CoTSE:4552 +0.57%46 EV-to-EBITDA is 22.09 as of Sep. 07, 2026, which is 39% below its 10-year median of 36.10. GuruFocus rates TSE:4552 with a GF Score™ of 46/100 and a GF Value™ of 円787.71 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 726 Drug Manufacturers companies, JCR Pharmaceuticals Co ranks worse than 70.52% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, JCR Pharmaceuticals Co's enterprise value is 円108,755 Mil.
JCR Pharmaceuticals Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was 円4,924 Mil. Therefore, JCR Pharmaceuticals Co's EV-to-EBITDA for today is 22.09.
The historical rank and industry rank for JCR Pharmaceuticals Co's EV-to-EBITDA or its related term are showing as below:
TSE:4552'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -291.79 Med: 36.1 Max: 227.4
Current: 22.09
During the past 13 years, the highest EV-to-EBITDA of JCR Pharmaceuticals Co was 227.40. The lowest was -291.79. And the median was 36.10.
TSE:4552's EV-to-EBITDA is ranked worse than 70.52% of 726
companies
in the Drug Manufacturers industry
Industry Median: 13.56
vs TSE:4552: 22.09
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
JCR Pharmaceuticals Co (TSE:4552) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
JCR Pharmaceuticals Co's PE Ratio (TTM) for today is calculated as:
JCR Pharmaceuticals Co's share price for today is 円528.00.
JCR Pharmaceuticals Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円6.700.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4552 vs LLY, JNJ, ABBV: EV-to-EBITDA Comparison
For the Drug Manufacturers - General subindustry, JCR Pharmaceuticals Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
JCR Pharmaceuticals Co EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, JCR Pharmaceuticals Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where JCR Pharmaceuticals Co's EV-to-EBITDA falls into.
JCR Pharmaceuticals Co's current Enterprise Value is 円108,755 Mil.
JCR Pharmaceuticals Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円4,924 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
JCR Pharmaceuticals Co (TSE:4552) has a EV-to-EBITDA of 22.09 as of Sep. 07, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on JCR Pharmaceuticals Co. This is 39% below median its historical median of 36.10. According to the industry distribution chart, JCR Pharmaceuticals Co ranks #512 out of 726 companies in the Drug Manufacturers industry, placing it in the top 70.5%.
Is JCR Pharmaceuticals Co's EV-to-EBITDA too high?
JCR Pharmaceuticals Co's current EV-to-EBITDA of 22.09 is 39% below median its 10-year median of 36.10. The Drug Manufacturers industry median EV-to-EBITDA is 13.56. JCR Pharmaceuticals Co's value of 22.09 is 62.9% above this industry median. Based on the distribution chart, JCR Pharmaceuticals Co ranks #512 out of 726 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, JCR Pharmaceuticals Co has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does JCR Pharmaceuticals Co's EV-to-EBITDA compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, JCR Pharmaceuticals Co ranks #512 out of 726 companies for EV-to-EBITDA. This places JCR Pharmaceuticals Co in the lower half of its industry. The industry median EV-to-EBITDA is 13.56. JCR Pharmaceuticals Co's value of 22.09 is 62.9% above this benchmark. While the company's 10-year median is 36.10 vs. the industry median of 13.56, JCR Pharmaceuticals Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.56, based on 726 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. JCR Pharmaceuticals Co's current EV-to-EBITDA of 22.09 is 62.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on JCR Pharmaceuticals Co. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. JCR Pharmaceuticals Co's current EV-to-EBITDA is 22.09, which is 39% below median its own 10-year median of 36.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is JCR Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, JCR Pharmaceuticals Co (TSE:4552) is currently considered Possible Value Trap. The stock's GF Value™ is 円787.71, compared to a current price of 円528.00 — trading 33% below its estimated fair value. The current EV-to-EBITDA is 22.09, which is 39% below median its 10-year median of 36.10 and 62.9% above the Drug Manufacturers industry median of 13.56. JCR Pharmaceuticals Co's overall GF Score™ is 46/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For JCR Pharmaceuticals Co (TSE:4552), the current EV-to-EBITDA is 22.09 as of Sep. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is JCR Pharmaceuticals Co (TSE:4552) Overvalued in 2026?
Based on GuruFocus' analysis, JCR Pharmaceuticals Co stock appears to be undervalued.
The current stock price of 円528.00 is trading 33% below its estimated GF Value™ of 円787.71.
GuruFocus considers JCR Pharmaceuticals Co to be Possible Value Trap.
Key valuation signals for TSE:4552:
EV-to-EBITDA: 22.09 (39% below median its 10-year median of 36.10)
GF Value™: 円787.71 vs. price of 円528.00 (33% below fair value)
Industry Position: 62.9% above the Drug Manufacturers median (#512 of 726)
No single metric tells the full story. See the TSE:4552 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
JCR Pharmaceuticals Co Ltd is a major drug manufacturing company proactively engaged in the research of enzymes and proteins. The company maintains a focus toward developing value-added treatment options to address unmet medical needs. JCR utilizes international partnerships as a component of its growth strategy. The vast majority of JCR's revenue is generated from its pharmaceutical operations, followed by medical devices and laboratory equipment. A portion of the company's sales are derived from licensing agreements.
46GF Score
Get the complete analysis for TSE:4552
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4552 has been successfully added to your 
